Featured Story | Friday, September 8, 2017 With five PD-1/PD-L1 inhibitors already on the market, new entrants are looking increasingly like the "me-too" brigade, but Regeneron and Sanofi have found a niche for their cemiplimab candidate—and snagged FDA breakthrough status to boot. |
|
| Top Stories Friday, September 8, 2017 Replimune has raised $55 million to generate clinical proof-of-concept data on its lead oncolytic immunotherapy. The series B round equips the team that led BioVex to a $1 billion buyout by Amgen and took Imlygic up to phase 3 to take another crack at developing a cancer-fighting virus. Friday, September 8, 2017 Boehringer Ingelheim has committed up to €250 million ($300 million) to work with Gubra on obesity treatments. The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides. Thursday, September 7, 2017 One of the biggest success stories in immuno-oncology in recent years is the rise of checkpoint inhibitors: drugs that inhibit proteins that would normally prevent immune cells from recognizing and attacking cancer. But they don't work in all patients. Now two research teams are testing companion therapies that might boost the effectiveness of these drugs. Friday, September 8, 2017 WuXi NextCODE has raised $240 million in a series B round. The investment sets the genomics company up to build out its platform and strike precision medicine and diagnostics partnerships to grow its user base and data repository. Thursday, September 7, 2017 In this week's EuroBiotech Report, a CAR-T death rocks Cellectis, NuCana and Nightstar file for Nasdaq IPOs and more. Friday, September 8, 2017 Eli Lilly is shuttering its R&D center in Shanghai amid a major overhaul, OrbiMed has set up its third Asia-focused biopharma and healthcare fund worth around $551 million, Takeda signed a deal for Japanese startup Noile-Immune's CAR-T pipeline and more. Friday, September 8, 2017 R&D chief Narsimhan will replace retiring Jimenez as Novartis CEO, Stada named industry veteran Albrecht as its fourth CEO in less than two years, Vertex poaches CFO Graney from Ironwood, plus more hirings, firings and retirings throughout the industry. This week's sponsor is FierceBiotech. | | FierceBiotech Executive Summit- London Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. | Resources Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Presented By: Decision Resources Group Uncover the true power of patient-centric data with this valuable industry resource. Click here to discover more 2nd Strategic Partnerships for Drug Repurposing October 26-27, 2017 | Boston, MA Compliance Certificate and Training for Life Sciences Professionals October 9 -12, 2017 | Newark, NJ CBI’s MedComm 2017 Conference October 26-27, 2017 | San Francisco, CA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London 11th Digital Pharma East October 3-6, 2017 | Philadelphia, PA Now Accepting Applications: Fierce Innovation Awards - Life Sciences Edition Deadline to Apply: Friday, October 20th, at 11:59 PM EST Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |